Full-Time

Medical Science Liaison Rare Disease

Updated on 4/18/2025

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops therapies for neurological disorders

Compensation Overview

$138.7k - $220k/yr

+ Bonus + Equity Awards

Mid, Senior

Nashville, TN, USA + 2 more

More locations: Charlotte, NC, USA | Atlanta, GA, USA

Candidates must be based in Georgia, North Carolina, or Tennessee.

Category
Nursing & Allied Health Professionals
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Advanced degree (MD, PharmD, PhD) in a scientific discipline or related field
  • 5 years of progressively responsible experience within the pharmaceutical or biotech industry
  • Focus on rare diseases, epilepsy, neurology or psychiatry is strongly preferred
  • Previous MSL experience desired
  • An equivalent combination of relevant education and experience may be considered
Responsibilities
  • Identifies and develops relationships with national and regional medical and scientific thought leaders, patient advocacy groups, and centers of excellence consistent with the strategy and objectives of Acadia’s Medical Affairs Development
  • Engages national and regional thought leaders to align interests, discuss research and medical information, and participate in scientific exchange and education about current and emerging therapies
  • Provides research trial site support and investigator-initiated research proposal cultivation and facilitation
  • Develops and maintains scientific, clinical and therapeutic expertise for Acadia’s portfolio
  • Cross-functionally collaborates, following all compliance guidelines, with regional field leadership partners including Regional Business Leaders (RBL) and Account Business Managers (ABMs)
  • Provides strategic field insights
  • Identifies disease concepts and compound characteristics that can be leveraged into product differentiation
  • Provide appropriate scientific, clinical, and educational support for internal and external clients
  • Represents the company at specific continuing educational events, programs, medical meetings and conventions
  • Supports Commercial operations by participating in Speaker and Sales Representative Training
  • Partners with the internal departments to ensure accurate delivery of medical and scientific information
  • Performs other duties as assigned
Desired Qualifications
  • Knowledge of regulatory, compliance, commercial, and clinical issues affecting the pharmaceutical and managed care industries
  • Knowledge of customer segments and market dynamics
  • Excellent planning and organizational skills
  • Ability to work independently and with cross-functional teams
  • Excellent oral and written communication skills, including presentation and facilitation formats
  • Demonstrated expertise in drug information communication
  • Skilled at negotiating with business partners or management and influencing leaders
  • Highly skilled and proficient with all MS Suites programs, including Outlook, Word, Excel, and PowerPoint
  • Ability to travel up to 75% of time, with primary residence within the territory area
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these conditions while also promoting diversity and inclusion within their operations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on personalized medicine benefits Acadia's tailored CNS therapies.
  • FDA's supportive regulatory environment aids Acadia's innovative CNS disorder treatments.
  • Growing interest in rare diseases supports Acadia's Rett syndrome treatment efforts.

What critics are saying

  • Increased competition from Biogen and Roche may impact Acadia's market share.
  • Litigation risks from class action lawsuit could lead to financial liabilities.
  • Challenges in DAYBUE's market adoption and reimbursement negotiations may affect commercialization.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on CNS disorders with a strong pipeline including pimavanserin.
  • The company collaborates with Biovail and Stoke Therapeutics for innovative drug development.
  • Acadia's DAYBUE is a pioneering treatment for Rett syndrome in the U.S.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
ETF Daily News
Mar 27th, 2025
Cibc World Markets Corp Invests $206,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Cibc World Markets Corp invests $206,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."